Takeda's Kapidex: Can A Study On Plavix Shake Up The PPI Market?
This article was originally published in PharmAsia News
Executive Summary
Takeda could position Kapidex as the proton pump inhibitor of choice if a new clinical trial confirms its interaction profile is more agreeable than other PPI products